×
Components:
Tamsulosin Hydrochloride
Method of action:
Alpha-Adrenergic Blocking, Alpha-Adrenolytic, Antidisuric, Normalizing The Function Of The Prostate, Urologicals
Available in countries
See all
close
Medically reviewed by Fedorchenko Olga Valeryevna, Pharmacy-Provisor. Last updated on 2019.09.15

Name of the medicinal product

Aclosan

Qualitative and quantitative composition

Tamsulosin Hydrochloride

Dosage (Posology) and method of administration

The information provided in Dosage (Posology) and method of administration of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Dosage (Posology) and method of administration in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

Posology

One capsule daily after breakfast or after the first daily meal.

Hepatic/renal impairment

No dose adjustment is warranted in renal impairment.

No dose adjustment is warranted in patients with mild to moderate hepatic insufficiency.

Paediatric population

The safety and efficacy of Aclosan hydrochloride in children < 18 years have not been established.

Method of administration

Oral use.

The capsule is swallowed whole, without crushing or chewing, because otherwise the controlled release of the active ingredient would be affected.

Contraindications

The information provided in Contraindications of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Contraindications in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close
<

- History of orthostatic hypotension.

- Severe hepatic insufficiency.

- Micturition syncope history

Special warnings and precautions for use

The information provided in Special warnings and precautions for use of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Special warnings and precautions for use in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

As with other α1-adrenoceptors antagonists, a reduction in blood pressure can occur in individual cases during treatment with Aclosan hydrochloride as a result of which, rarely, syncope can occur. At the first signs of orthostatic hypotension (dizziness, weakness), the patient should sit or lie down until the symptoms have disappeared.

Before therapy with Aclosan hydrochloride is initiated, the patient should be examined in order to exclude the presence of other conditions, which can cause the same symptoms as benign prostatic hyperplasia. Digital rectal examination and, when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular intervals afterwards.

The treatment of patients with severe renal impairment (creatinine clearance of < 10 ml/min) should be approached with caution, as these patients have not been studied.

Angioedema has been rarely reported after the use of Aclosan. In case of angioedema, treatment should be discontinued immediately, the patient should be monitored until disappearance of the oedema, and Aclosan should not be re-administered.

The 'Intraoperative Floppy Iris Syndrome' (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with Aclosan hydrochloride. IFIS may increase the risk of eye complications during and after the operation.

Discontinuing Aclosan hydrochloride 1 - 2 weeks prior to cataract surgery is anecdotally considered helpful, but the benefit of treatment discontinuation has not yet been established. IFIS has also been reported in patients who had discontinued Aclosan for a longer period prior to cataract surgery.

The initiation of therapy with Aclosan hydrochloride in patients for whom cataract surgery is scheduled is not recommended. During pre-operative assessment, cataract surgeons and ophthalmic teams should consider whether patients scheduled for cataract surgery are being or have been treated with Aclosan in order to ensure that appropriate measures will be in place to manage the IFIS during surgery.

Aclosan hydrochloride should not be given in combination with strong inhibitors of CYP3A4 in patients with poor metaboliser CYP2D6 phenotype.

Aclosan hydrochloride should be used with caution in combination with strong and moderate inhibitors of CYP3A4.

Effects on ability to drive and use machines

The information provided in Effects on ability to drive and use machines of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Effects on ability to drive and use machines in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

No studies on the effects on the ability to drive and use machines have been performed. However, patients should be aware of the fact that dizziness can occur.

Undesirable effects

The information provided in Undesirable effects of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Undesirable effects in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

Tabulated list of adverse reactions

The frequency of adverse reactions of Aclosan listed below is defined using the following convention: Common (> 1/100 to < 1/10); uncommon (> 1/1,000 to < 1/100); rare (> 1/10,000 to < 1/1,000); very rare (< 1/10,000), not known (cannot be estimated from the available data).

MedDRA system organ class

Frequency

Adverse reaction

Nervous system disorders

Common

Dizziness (1.3%)

Uncommon

Headache

Rare

Syncope

Eye disorders

Not known

Vision blurred*, visual impairment*

Cardiac disorders

Uncommon

Palpitations

Vascular disorders

Uncommon

Orthostatic hypotension

Respiratory, thoracic and mediastinal disorders

Uncommon

Rhinitis

Not known

Epistaxis*

Gastrointestinal disorders

Uncommon

Constipation, diarrhoea, nausea, vomiting

Not known

Dry mouth*

Skin and subcutaneous tissue disorders

Uncommon

Rash, pruritus, urticaria

Rare

Angioedema

Very rare

Stevens-Johnson syndrome

Not known

Erythema multiforme*, dermatitis exfoliative*

Reproductive system and breast disorders

Common

Ejaculation disorder, retrograde ejaculation, ejaculation failure

Very rare

Priapism

General disorders and administration site conditions

Uncommon

Asthenia

* Observed post-marketing.

Post-marketing experience: In addition to the adverse events listed above, atrial fibrillation, arrhythmia, tachycardia and dyspnoea have been reported in association with Aclosan hydrochloride use. Because these spontaneously reported events are from the worldwide post marketing experience, the frequency of events and the role of Aclosan in their causation cannot be reliably determined.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.

Overdose

The information provided in Overdose of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Overdose in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

Symptoms

Overdosage with Aclosan hydrochloride can potentially result in severe hypotensive effects. Severe hypotensive effects have been observed at different levels of overdosing.

Treatment

In case of acute hypotension occurring after overdosage cardiovascular support should be given. Blood pressure can be restored and heart rate brought back to normal by lying the patient down. If this does not help then volume expanders and, when necessary, vasopressors could be employed. Renal function should be monitored and general supportive measures applied. Dialysis is unlikely to be of help as Aclosan is very highly bound to plasma proteins.

Measures, such as emesis, can be taken to impede absorption. When large quantities are involved, gastric lavage can be applied and activated charcoal and an osmotic laxative, such as sodium sulphate, can be administered.

Pharmacodynamic properties

The information provided in Pharmacodynamic properties of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Pharmacodynamic properties in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

Pharmacotherapeutic category: Adrenergic α1-receptors antagonist.

ATC: G04CA02.

The product is designed exclusively for the treatment of diseases of the prostate.

Mechanism of action

Aclosan binds selectively and competitively to post-synaptic α1-adrenoreceptors, prevailingly their subtypes designated α1A and α1D. Thus relaxation of smooth muscles of the prostate and urethra is achieved, which leads to a reduction of tonus and an improvement of the urinary flow.

Pharmacodynamic effects

Aclosan increases the maximum urinary flow. Due to relaxation of smooth muscles in the prostate and the urethra, obstruction is decreased, which leads to alleviation of voiding symptoms.

Aclosan also alleviates the storage symptoms in the development of which also the instability of the urinary bladder is involved at a significant extent. The effects on symptoms of filling and depletion of the urinary bladder persist during long-term treatment. The necessity of surgical treatment or catheterization is significantly delayed owing to these effects.

α1-blockers can reduce blood pressure by lowering peripheral resistance. No reduction in blood pressure of any clinical significance was observed during studies with Aclosan in normotensive patients.

Paediatric population

A double-blind, randomized, placebo-controlled, dose ranging study was performed in children with neuropathic bladder. A total of 161 children (with an age of 2 to 16 years) were randomized and treated at 1 of 3 dose levels of Aclosan (low [0.001 to 0.002 mg/kg], medium [0.002 to 0.004 mg/kg], and high [0.004 to 0.008 mg/kg]), or placebo. The primary endpoint was number of patients who decreased their detrusor leak point pressure (LPP) to < 40 cm H2O based upon two evaluations on the same day. Secondary endpoints were: Actual and percent change from baseline in detrusor leak point pressure, improvement or stabilization of hydronephrosis and hydroureter and change in urine volumes obtained by catheterisation and number of times wet at time of catheterisation as recorded in catheterisation diaries. No statistically significant difference was found between the placebo group and any of the 3 Aclosan dose groups for either the primary or any secondary endpoints. No dose response was observed for any dose level.

Pharmacokinetic properties

The information provided in Pharmacokinetic properties of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Pharmacokinetic properties in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

Absorption

Aclosan is absorbed from the intestinal tract and its bioavailability is almost complete. The absorption of Aclosan decreases if the product is administered shortly after the meal. The uniformity of absorption may be supported via using the product Aclosan capsules always after the same daily meal.

Kinetics of Aclosan is linear.

After a single dose of Aclosan taken after a full meal, the peak plasma levels are achieved at approximately 6 hours. The steady state is reached by day five of multiple dosing, when Cmax in patients is about two thirds higher than that reached after a single dose. Although this has been demonstrated only in the elderly, the same result would also be expected in younger patients.

There are huge inter-patient variations in plasma levels of Aclosan, both after single as well as multiple dosing.

Distribution

In humans, approximately 99% of Aclosan is bound to plasma proteins and its distribution volume is small (approximately 0.2 l/kg).

Biotransformation

Aclosan has a low first pass metabolic effect. The majority of Aclosan is present in plasma in an unchanged form. Aclosan is metabolized in the liver.

In studies on rats, an induction of microsomal liver enzymes induced by Aclosan has not been practically observed.

In vitro results suggest that CYP3A4 and also CYP2D6 are involved in metabolism, with possible minor contributions to Aclosan hydrochloride metabolism by other CYP isozymes. Inhibition of CYP3A4 and CYP2D6 drug metabolizing enzymes may lead to increased exposure to Aclosan hydrochloride.

Dosage adjustment is not necessary in mild hepatic insufficiency.

The metabolites are not as effective and toxic as the active medicinal product itself.

Elimination

Aclosan and its metabolites are mainly excreted in the urine; approximately 9% of the dose given is released in an unchanged form.

The elimination half-life of Aclosan in patients is approximately 10 hours (when taken after a meal) and 13 hours in the steady state.

In case of renal affections, no reduction of Aclosan doses is substantiated.

Preclinical safety data

The information provided in Preclinical safety data of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Preclinical safety data in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

Toxicity after a single dose and multiple dosing has been investigated in mice, rats and dogs. Reproductive toxicity has also been investigated in rats, carcinogenicity in mice and rats, and genotoxicity in vivo and in vitro. The common toxicity profile with large doses of Aclosan is equivalent to the pharmacological effect associated with alpha adrenergic antagonists.

Changes in ECG readings were found with very large doses in dogs. This is not, however, assumed to be of any clinical significance. Aclosan has not been found to have any significant genotoxic properties.

An increased incidence of proliferative alterations in the mammary glands of rat and mice females has been found. These findings, which are probably indirectly linked to hyperprolactinaemia and only occur as a result of large doses having been taken, are considered clinically insignificant.

Incompatibilities

The information provided in Incompatibilities of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Incompatibilities in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

Not applicable.

Special precautions for disposal and other handling

The information provided in Special precautions for disposal and other handling of Aclosan is based on data of another medicine with exactly the same composition as the Aclosan of the medicine (Tamsulosin Hydrochloride). Be careful and be sure to specify the information on the section Special precautions for disposal and other handling in the instructions to the drug Aclosan directly from the package or from the pharmacist at the pharmacy.
more... close

No special requirements.